Carande Carl Steven
Known title: DirectorCIK: 0002146558
Carande Carl Steven's purchase track record
Carande Carl Steven has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/10/2026 | UCB | $74K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| UCB | ▲ Buy | Open Market | 2,101 | $74K | 8/10/2026 | View on chart |
| UCB | ▲ Buy | Grant | 1,588 | $0 | 8/1/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
UCB Announces Georgia Biologics Campus and Strong Q3 Activity
United Community Banks has dedicated a site in Georgia for a new U.S. biologics manufacturing campus, expanding its presence in the biotech sector. A recent review notes a busy third quarter that could set the bank up for better financial results. These developments come as the stock trades near its 52‑week high and shows modest momentum on technical indicators.
UCB Announces Georgia Biologics Campus and Strong Q3 Activity. United Community Banks has dedicated a site in Georgia for a new U.S. biologics manufacturing campus, expanding its presence in the biotech sector. A recent review notes a busy third quarter that could set the bank up for better financial results. These developments come as the stock trades near its 52‑week high and shows modest momentum on technical indicators.